Anti-SARS-CoV-2 Spike S1 Antibody |
A3000-50 |
Biovision |
50 µg |
EUR 502.8 |
Human IgG antibody Laboratories manufactures the sars spike s1 antibody reagents distributed by Genprice. The Sars Spike S1 Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Antibody. Other Sars products are available in stock. Specificity: Sars Category: Spike Group: S1 Antibody
Rabbit monoclonal Anti-MERS Spike protein (S1/RBD/MERS-RBD) IgG (Neutralizing) |
Alpha Diagnostics |
100 ul |
EUR 781.2 |
Mouse monoclonal Anti-MERS Spike protein (S1/18-725aa) IgG (clone 1) |
Alpha Diagnostics |
100 ul |
EUR 578.4 |
Mouse monoclonal Anti-MERS Spike protein (S1/18-725aa) IgG (clone 2) |
Alpha Diagnostics |
100 ul |
EUR 578.4 |
Spike S1, Fc fusion (SARS-CoV-2) |
BPS Bioscience |
50 µg |
EUR 505 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa. |
Recombinant SARS-CoV-2 Spike S1 Protein with hFc and His-Tag |
EpiGentek |
100 ul |
EUR 518.1 |
Recombinant SARS-CoV-2 Spike S1 Protein with His and Avi Tag |
EpiGentek |
100 ul |
EUR 518.1 |
Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2) |
BPS Bioscience |
100 µg |
EUR 460 |
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
S1 Antibody information
Anti-SARS-CoV-2 Spike S1 Antibody |
A3000-50 |
Biovision |
50 µg |
EUR 502.8 |
SARS-CoV spike protein Antibody |
abx023139-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
SARS-CoV spike protein Antibody |
abx023143-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
Spike S1 (16-685), Fc fusion (SARS-CoV-2) |
100688-1 |
BPS Bioscience |
20 µg |
EUR 405 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa. |
Spike S1 RBD, His-tag (SARS-CoV-2) |
100687-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, His-tag (SARS-CoV-2) |
100687-2 |
BPS Bioscience |
100 µg |
EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
100699-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
100699-2 |
BPS Bioscience |
100 µg |
EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
SARS-CoV-2 (COVID-19) Spike Antibody |
3525-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike Antibody |
3525-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Spike Trimer (S1+S2), His-tag (SARS-CoV) |
100789-1 |
BPS Bioscience |
100 µg |
EUR 450 |
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Spike Trimer (S1+S2), His-tag (SARS-CoV) |
100789-2 |
BPS Bioscience |
500 µg_x000D_ |
EUR 1900 |
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
SARS Spike Peptide |
3219P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) SARS Spike peptide |
SARS Spike Peptide |
3525P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) SARS Spike peptide |
SARS-CoV-2 Spike Monoclonal Antibody |
A73664 |
EpiGentek |
|
|
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
9119-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
9119-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |